Low-level laser therapy and unloading curative gymnastics in the complex treatment of severe arterial hypertension

Purpose: To study effectiveness of low-level laser therapy (LLLT) and unloading curative gymnastics (UCG) in the treatment of patients with severe arterial hypertension (AH). Material and methods. 58 patients with severe hypertension were divided into two comparable groups: studied group – 30 patients who had LLLT and UCG; control group – 28 patients who had only supportive medicamentous therapy. In both groups, before and after treatment, the following parameters were registered: systolic, diastolic, mean pressure; regional vascular resistance at rest and at the peak of reactive hyperemia; venous tone and blood flow at rest and at the peak of reactive hyperemia. UCG was personalized for each patient. Before UCG, patients had LLLT sessions with red and infrared laser light up to 20 minutes. LLLT course had 10–15 sessions. Results. Initially, in both groups, there was revealed a significant increase in systolic, diastolic, mean arterial pressure and the increase in regional vascular resistance at rest and at the peak of reactive hyperemia; the venous tone under reduced blood flow was decreased at rest as well as the reserve blood flow. After treatment, in the studied group, there was a significant increase in blood flow at rest and in the reserve blood flow; decrease in regional vascular resistance at rest and under functional loading test and in venous tone; decrease of systolic, diastolic and mean arterial pressure. A significant reduction in blood pressure in the studied group was accompanied by the evident improvement in patients’ clinical status and by the improvement of their quality of life. In the control group there was no positive dynamics. Conclusion. LLLT and UCD in the complex treatment of patients with severe hypertension correct the peripheral vascular system manifested with a reliable increase of blood flow at rest and the reserve blood flow; decrease of the peripheral vascular resistance at rest and under functional loading tests; decrease in the venous tone. These positive changes contributed to a significant decrease of blood pressure parameters: systolic, diastolic and mean.

1. Achilova Sh.A., Achilov A.A., Lebedeva O.D. et al. Low-level laser therapy and unloading curative gymnastics in the treatment of patients with arterial hypertension. Proceedings of scientifc conference dedicated to the 30-th year anniversary of Skobelkin State Scientifc Center of Laser Medicine. Lasernaya medicina. 2016; 3: 57–58.

2. Achilov A.A. A technique to unload the working heart, to increase blood flow, to restore the restore and total exchange surface of capillaries in various areas of the body at the level of regional hemodynamics. Eurasian Patent No. 004621 dated June 24, 2004: 16.

3. Kobalava Z.D., Kotovskaya Yu.V. Hypertension: keys to diagnosis and treatment. Moscow, GEOTAR-MEDIA, 2009: 864.

4. Kukes V.G., Sychev D.A., Starodubtsev A.K., Ramenskaya G.V., Maksimov M.L. et al. Clinical pharmacology: A textbook for students of medical universities. Moscow, GEOTAR-MEDIA, 2009: 866.

5. Leonova M.V., Belousov Yu.B., Shteinberg L.L. et al. Analysis of pharmacotherapy of arterial hypertension by the data received in the study PIFAGOR III / / Farmateka. 2010: 87–95.

6. Maksimov M.L., Starodubtsev A.K., Svetly L.I. Amlodipine in the treatment of arterial hypertension. Rosijsky meditzinsky zhurnal. 2006; 14 (10): 777–781.

7. Maximov M.L. Clinical and pharmacological approaches to the regulation of the activity of renin-angiotensin-aldosterone system in patients with arterial hypertension and chronic kidney disease: Abstract to dissertation for Doctor of Medical Sciences. Moscow, 2011: 48.

8. Russian recommendations «Diagnostics and treatment of arterial hypertension» (4th revision). Systemic Hypertension. 2010 (3): 5–26.

9. Brown M.J., Palmer C.R., Castaigne A. et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000; 35: 366–372.

10. Carlsberg B., Samuelsson O., Lindholm L.H. Atenolol in hypertension: is it a wise choice? Lancet. 2004; 364: 1684–1689.

11. Chobanian A.V., Bakris G.L. et al. Seventh report of the Joint National Committee of prevention, detection, evaluation and treatment of high blood pressure. Hypertension. 2003; 42: 1206–1252.

12. Dahlöf B., Sever P.S., Poulter N.R. et al. ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of Amlodipine adding Perindopril as required versus Atenolol adding Bendroflumethiazide as required, in the AngloScandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005; 366: 895–906.

13. Davis B.R., Culter J.A., Gordon D.J. et al. Major cardiovascular events in hypertensive patients randomized to Doxazosin vs Chlorthalidone, JAMA. 2000, Apr.; 19, 283 (15): 1967–1975.

14. Khan N., McAlister F.A. Re-examining the effcacy of β-blockers for the treatment of hypertension: a meta-analysis. CMAJ. 2006; 12: 1737–1742.

15. 2013 European Society of Hypertension – European Society of Cardiology. Guidelines for the management of arterial hypertension. J. Hypertens. 2013; 7: 1281–1357.